An interview with a US-based key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Idhifa, Tibsovo, magrolimab, quizartinib, crenolanib, gilteritinib, and uproleselan.
Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report By Disease (Myeloblastic Leukemia, Myelomonocytic Leukemia), By Treatment (Chemotherapy), By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030
- Report
- 175 Pages
- Global
